Back to results
US 10,407,666 B2Granted
Recombinant vectors
AssigneeTocagen Inc.
InventorsHarry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
Life of this patent
Estimating the term…
Abstract
This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
Claims10
A recombinant replication competent gammaretrovirus comprising:
- a gammaretroviral GAG protein;
- a gammaretroviral POL protein;
- a gammaretroviral envelope;
- a gammaretroviral RNA polynucleotide comprising 3′ untranslated region (U3) and repeat region (R) sequences from murine leukemia virus (MLV), Moloney murine leukemia virus (MoMLV), Feline leukemia virus (FeLV), Baboon endogenous retrovirus (BEV), porcine endogenous virus (PERV), the cat derived retrovirus RD114, squirrel monkey retrovirus, Xenotropic murine leukemia virus-related virus (XMRV), avian reticuloendotheliosis virus (REV), or Gibbon ape leukemia virus (GALV) at the 3′ end of the gammaretroviral polynucleotide sequence, an R and 5′ untranslated region (U5) sequence from MLV, MoMLV, FeLV, BEV, PERV, RD114, squirrel monkey retrovirus, XMRV, REV or GALV at the 5′ end of the gammaretroviral polynucleotide, a gag nucleic acid domain, a pol nucleic acid domain and an env nucleic acid domain from MLV, MoMLV, FeLV, BEV, PERV, RD114, squirrel monkey retrovirus, XMRV, REV or GALV located between the U5 and U3 regions;
- a cassette comprising an internal ribosome entry site (IRES) upstream and operably linked to a heterologous polynucleotide encoding an antibody or antibody fragment, wherein the cassette is positioned 5′ to the U3 region and 3′ to the env nucleic acid domain;
- and
- cis-acting sequences necessary for reverse transcription, packaging and integration in a target cell.
4 more elements
Dependencies are inferred from the claim text.